Intermittent schedules of the oral RAFâ€“MEK inhibito RAS/RAF-mutant solid tumours and multiple myeloma dose-escalation and basket dose-expansion study

Lancet Oncology, The

21, 1478-1488

DOI: 10.1016/s1470-2045(20)30464-2

Citation Report

#	Article	IF	Citations
1	Surufatinib â€" a novel oral agent for neuroendocrine tumours. Nature Reviews Endocrinology, 2021, 17, 9-10.	4.3	10
2	Resistance to Molecularly Targeted Therapies in Melanoma. Cancers, 2021, 13, 1115.	1.7	36
3	Pathway-Directed Therapy in Multiple Myeloma. Cancers, 2021, 13, 1668.	1.7	15
4	Considerations on the mechanics and sample sizes for early trials of targeted agents and immunotherapy in oncology. Expert Review of Precision Medicine and Drug Development, 2021, 6, 271-280.	0.4	0
5	Searching for treatments for non-G12C-KRAS mutant cancers. British Journal of Cancer, 2021, 125, 625-626.	2.9	4
6	Emerging strategies to target RAS signaling in human cancer therapy. Journal of Hematology and Oncology, 2021, 14, 116.	6.9	98
7	Novel RAF/MEK inhibitor CH5126766/VSâ€6766 has efficacy in combination with eribulin for the treatment of tripleâ€negative breast cancer. Cancer Science, 2021, 112, 4166-4175.	1.7	6
8	Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer and Metastasis Reviews, 2021, 40, 819-835.	2.7	41
9	Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS. Pharmacological Research, 2021, 172, 105806.	3.1	17
10	Pharmacogenomics in solid cancers and hematologic malignancies: improving personalized drug prescription. Therapie, 2021, , .	0.6	1
11	Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. Cancer Discovery, 2022, 12, 924-937.	7.7	110
12	KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders. Cancers, 2022, 14, 666.	1.7	8
13	Targeting KRAS G12C mutation in lung adenocarcinoma. Lung Cancer, 2022, 165, 28-33.	0.9	10
14	Future Developments in the Treatment of AL Amyloidosis. Hemato, 2022, 3, 131-152.	0.2	2
15	Targeting KRAS in NSCLC: Old Failures and New Options for â€œNon-G12câ€•Patients. Cancers, 2021, 13, 6332.	1.7	10
16	Klinische Studien auf der Basis molekularer Charakterisierung von Tumoren. Springer Reference Medizin, 2021, , 1-57.	0.0	0
17	Discovery of the First-in-Class Mek Inhibitor Trametinib (Trade Name: Mekinist) and Other Molecular Targeting Agents by â€œRb-Reactivator Screeningâ€• SSRN Electronic Journal, 0, , .	0.4	0
18	Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy. Molecules, 2021, 26, 7561.	1.7	3

#	Article	IF	Citations
19	New progress in the mechanism of microenvironment-driven chemoradiotherapy resistance in digestive system tumors. World Chinese Journal of Digestology, 2022, 30, 341-348.	0.0	0
20	Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules. Trends in Pharmacological Sciences, 2022, 43, 866-881.	4.0	13
21	â€œRB-reactivator screeningâ€•as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist). , 2022, 236, 108234.		4
22	BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it. Clinical and Translational Oncology, 2023, 25, 10-20.	1.2	9
23	Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer. Cancer Treatment Reviews, 2022, 109, 102433.	3.4	15
24	The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers. Bioorganic and Medicinal Chemistry, 2022, 70, 116922.	1.4	3
25	Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation. Frontiers in Oncology, 0, 12, .	1.3	13
26	Multi or Single-Kinase Inhibitors to Counteract Drug Resistance in Cancer: What is New?. Current Medicinal Chemistry, 2023, 30, 776-782.	1.2	5
27	A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors. Exploration of Targeted Anti-tumor Therapy, 0, , 463-479.	0.5	3
28	Small molecule inhibitors targeting the cancers. MedComm, 2022, 3, .	3.1	25
29	Drugging KRAS: current perspectives and state-of-art review. Journal of Hematology and Oncology, 2022, 15, .	6.9	34
30	KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions. Cells, 2023, 12, 749.	1.8	5
31	Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary. Oncologist, 2023, 28, 474-478.	1.9	0
36	Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	7
39	BRAF â€” a tumour-agnostic drug target with lineage-specific dependencies. Nature Reviews Clinical Oncology, 2024, 21, 224-247.	12.5	1